C4 Therapeutics Aims to Revolutionize Disease Treatment with Protein-Targeting Therapies
C4 Therapeutics is a biotech company focused on developing early-stage therapies to eliminate disease-causing proteins, with a market capitalization of $115.74 million and a stock price of $1.62 per share as of May 4, 2025.
2 minutes to read